These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3338011)

  • 21. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
    DiGiovanna MP; Stern DF; Edgerton S; Broadwater G; Dressler LG; Budman DR; Henderson IC; Norton L; Liu ET; Muss HB; Berry DA; Hayes DF; Thor AD
    J Clin Oncol; 2008 May; 26(14):2364-72. PubMed ID: 18390970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer.
    Alagaratnam TT; Wong J
    Aust N Z J Surg; 1986 Jan; 56(1):39-41. PubMed ID: 3090987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin.
    Nemoto T; Horton J; Simon R; Dao TL; Rosner D; Cunningham T; Sponzo R; Snyderman M
    Cancer; 1982 May; 49(10):1988-93. PubMed ID: 7074523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
    J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC).
    Ahmann FR; Jones SE; Moon TE; Hammond N; Miller TP; Durie BG
    Cancer; 1985 Aug; 56(4):730-7. PubMed ID: 4016669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
    N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
    Sparano JA; Wadler S; Liebes L; Robert NJ; Schwartz EL; Dutcher JP
    Cancer Res; 1993 Aug; 53(15):3509-12. PubMed ID: 8339255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
    Levine MN; Bramwell V; Abu-Zahra H; Goodyear MD; Arnold A; Findlay B; Skillings J; Gent M
    Br J Cancer; 1992 Jan; 65(1):130-2. PubMed ID: 1733435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
    Taguchi T; Sakai K; Terasawa T; Wada H
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
    Valagussa P; Tancini G; Bonadonna G
    Cancer; 1986 Oct; 58(7):1411-7. PubMed ID: 3755647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
    Hortobagyi GN; Buzdar AU; Frye D; Hug V; Fraschini G; Ames FC; Montague E; Gutterman JU; Martin RG
    Cancer; 1987 Dec; 60(11):2596-604. PubMed ID: 3315173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical adjuvant chemotherapy for breast cancer: a comparison of CMF and CAF regimens.
    Babar AM
    J Pak Med Assoc; 1991 Dec; 41(12):293-6. PubMed ID: 1824559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].
    Nomura Y; Abe O; Izuo M; Inoue K; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1863-71. PubMed ID: 3382238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.